Quantcast

Latest Nebulizer Stories

2010-09-16 17:48:32

There is no apparent link between asthma and tooth decay, according to a study published in the September 2010 issue of the Journal of the American Dental Association. "Is There a Relationship between Asthma and Dental Caries?: A Critical Review of the Literature" examined the 27 separate studies which looked for a link between asthma and cavities that were reported in 29 papers published between 1976 and March 2010. "The notion that there is a link between asthma and tooth decay may have its...

2010-06-21 11:56:00

MONTEREY, Calif., June 21 /PRNewswire/ -- In a head-to-head, Phase III clinical trial of Cayston delivered by the Altera Nebulizer System versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa, the co-primary endpoint of non-inferiority for mean percent change in forced expiratory volume in one second (FEV(1)) percent predicted after 28 days of treatment was achieved. Patients receiving Cayston had a mean increase in FEV(1) percent predicted from...

2010-06-17 12:22:00

MONMOUTH JUNCTION, N.J., June 17 /PRNewswire/ -- Transave, Inc., today reported interim results from a multi-cycle Phase II open label clinical trial in cystic fibrosis (CF) patients on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The data indicated that ARIKACE, delivered once daily for 28 consecutive days followed by 56 days off-treatment for four cycles demonstrated statistically significant improvement in lung function that was sustained during the...

2010-05-24 09:00:00

BEIJING, May 24 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM), an emerging leader in the development, assembly, marketing and sale of medical products in China, announced today an exclusive distributor agreement for HEYER Medical's Cumulus ultrasonic nebulizer in China. Dehaier is authorized to distribute all models of this product. HEYER Cumulus is suitable for the treatment of respiratory tract conditions such as asthma, bronchitis, chronic respiratory...

2010-05-24 06:00:00

MONMOUTH JUNCTION, N.J., May 24 /PRNewswire/ -- Transave Inc. today announced that the United States Patent and Trademark Office has issued an important composition of matter patent (U.S. Patent No. 7,718,189) for liposomal aminoglycoside formulations including its lead compound, ARIKACE(TM) (liposomal amikacin for inhalation). The company expects that the patent will provide exclusivity for ARIKACE until October 1, 2026. "The issuance of this composition of matter patent significantly...

2010-05-17 07:00:00

SAN DIEGO, May 17 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced the presentation of data from its Phase 2b clinical trial with Aeroquin(TM) (a proprietary aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF) at the American Thoracic Society (ATS) Annual Meeting in New Orleans. Trial results demonstrated statistically significant improvements in bacterial load, respiratory function and time to need for anti-pseudomonal antibiotics (a measure of exacerbations)...

2010-03-01 09:00:00

MIDLOTHIAN, Va., March 1 /PRNewswire/ -- Today, PARI Respiratory Equipment launched their newest aerosol delivery system, the Vios. Paired with PARI's gold standard reusable nebulizers, Vios delivers fast treatments, small particle size, and high respirable drug dose to the lungs. Vios also features an extended warranty and Timestrip, an easy to use reminder for patients to replace their nebulizer every six months. "We are excited for physicians treating respiratory diseases to begin...

2010-02-23 10:22:00

MONTEREY, Calif., Feb. 23 /PRNewswire/ -- Altera, which uses eFlow Technology, was cleared to market today by the FDA as the first drug-specific nebulizer for use in the treatment of patients with cystic fibrosis and has been specifically developed to deliver Gilead Sciences' Cayston (aztreonam for inhalation solution) 75 mg. Cayston is a new inhaled antibiotic that received marketing approval from the U.S. Food and Drug Administration (FDA) yesterday as a treatment to improve respiratory...

2010-02-22 20:48:00

CF Foundation's $1 Million Investment Helped Drug Known as Cayston(R) Become a Reality BETHESDA, Md., Feb. 22 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration approved an important new inhaled antibiotic called Cayston® (aztreonam for inhalation solution) today for the treatment of cystic fibrosis. The drug was made possible by significant support from the Cystic Fibrosis Foundation, including a $1 million investment by a Foundation subsidiary to help...

2010-02-11 09:00:00

MONTEREY, Calif., Feb. 11 /PRNewswire/ -- PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging. "We are very pleased to...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.